(Q53891579)

English

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. (English)

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

sodium stibogluconate

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

author name string

Rijal S

1

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Chappuis F

2

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Singh R

3

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Bovier PA

4

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Acharya P

5

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Karki BM

6

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Desjeux P

8

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Loutan L

9

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Koirala S

10

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

publication date

1 May 2003

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Transactions of the Royal Society of Tropical Medicine and Hygiene

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

97

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

350-354

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

3

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Visceral leishmaniasis control: a public health perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

A policy for leishmaniasis with respect to the prevention and control of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Monitoring drug resistance in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Leishmaniasis. Public health aspects and control

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

The increase in risk factors for leishmaniasis worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

A systematic review of current knowledge of HIV epidemiology and of sexual behaviour in Nepal

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Clinicoepidemiological study of drug resistance in Indian kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

21 January 2018

Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-course of oral miltefosine for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2803%2990167-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0035-9203(03)90167-2

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

1 reference

Europe PubMed Central

22 May 2018

http://europepmc.org/abstract/MED/15228258

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53891579&oldid=1725067003"